Recent developments in the field of pituitary gigantism, including the discovery of a new syndrome and genes related to this syndrome, were presented in a plenary session at the 58th Annual ESPE Meeting in Vienna, Austria.
The genetic causes of short stature are highly heterogenous and a new classification system for these children is needed, delegates were told at the 58th Annual ESPE Meeting in Vienna, Austria.
Growth hormone therapy in young children with Prader-Willi syndrome, genes linked to isolated short stature, and the role of insulin-like growth factor -2 in autoimmune disease are the subjects of three papers included in the 2019 Yearbook of Paediatric Endocrinology.
Oestrogen is key to the management of adolescents and young women with Turner syndrome, with hormone replacement therapy generally preferable to the contraceptive pill, delegates were told at the 58th Annual ESPE Meeting in Vienna, Austria.
A plenary session at the 58th Annual ESPE Meeting in Vienna, Austria, has highlighted how wide-ranging the risks associated with sleep and circadian rhythm disruption are.
Short stature management and growth hormone therapy in the Asia Pacific region
Click here to view the full on-demand webcast
This webcast will discuss the clini […]
During ESPE 2019 in Vienna, medwireNews reported on original research and symposium discussions covering a wide range of topics including the management of Turner syndrome in adolescents and young adults, the dynamics of childhood obesity, e-reporting of rare endocrine conditions, genetic disorders of growth, the importance of sleep, and novel monogenic forms of autoimmune diabetes.
Research focus: ‘Health not height’ – Trial results for a targeted treatment for children with achondroplasia
Professor Ravi Savarirayan talks through the recently published results in The New England Journal of Medicine for the C-type natriuretic peptide analogue vosiritide in children with achondroplasia.
In this podcast, Dr Shylaja Srinivasan discusses the care of children and adolescents with type 2 diabetes, and how the findings of the TODAY2 and Ellipse trials will inform treatment decisions.